GlaxoSmithKline PLC
featured
Simon Dingemans, Chief Financial Officer at GlaxoSmithKline says that the company's re-engineered approach to R&D is bearing fruit with pipeline looking very healthy.
» Read More
More
-
SANTA CLARA, Calif.-- Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June. Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions.
-
NEW YORK, May 16- The big four U.S. broadcast networks, in need of new TV hits to turn around slumping ratings, are betting espionage programs and old comedy stars will convince advertisers to spend about $9 billion during the so-called upfront selling season.
-
WILLIAMSBURG, Va.-- Changes in the marketplace have forced the public health community to wrestle with the idea that some tobacco products may pose less of a health risk than others, the new head of the Food and Drug Administration's tobacco control efforts told an industry group on Thursday.
-
LONDON, May 16- On approaching his 60th birthday this year, long-serving Tullow Oil boss Aidan Heavey told staff he felt "like two 30 year-olds". Peter Voser is giving up one of the world's most challenging CEO roles at Royal Dutch/Shell next year, before his 55th birthday, in pursuit of a "lifestyle change".
-
LONDON, May 16- On approaching his 60th birthday this year, long-serving Tullow Oil boss Aidan Heavey told staff he felt "like two 30 year-olds". Peter Voser is giving up one of the world's most challenging CEO roles at Royal Dutch/Shell next year, before his 55th birthday, in pursuit of a "lifestyle change".
-
Simon Dingemans, Chief Financial Officer at GlaxoSmithKline says that the company's re-engineered approach to R&D is bearing fruit with pipeline looking very healthy.
-
Yum Brands falls as monthly Chinese sales drop. NEW YORK, May 13- U.S. stocks closed little changed on Monday, pausing after hitting record highs last week, but strength in healthcare issues helped to keep declines in check.
-
*Yum Brands falls as monthly Chinese sales drop. NEW YORK, May 13- U.S. stocks ended flat on Monday, pausing after hitting record highs last week, but strength in healthcare issues helped to keep declines in check.
-
*Core U.S. retail sales rise 0.5 percent in April. *Yum Brands falls as monthly Chinese sales drop. NEW YORK, May 13- U.S. stocks were mostly flat on Monday as investors paused following a rally that took indexes to record highs, though a strong read on retail sales limited declines and the Nasdaq ticked up on a rally in Netflix.
-
*Elan to buy part of U.S. drug firm Theravance's royalty for $1 billion. NEW YORK, May 13- U.S. stocks dipped on Monday, retreating from the most recent record high, but an unexpected rise in retail sales last month muted declines.
-
*Elan, Theravance reach royalties deal. NEW YORK, May 13- U.S. stocks were poised for a lower open on Monday after the S&P 500 index closed at a record high, but an unexpected rise in retail sales last month was likely to curb any decline.
-
*Late payment hitting southern Europe harder than the north. *Business confidence down across Europe. Against the backdrop of the economic downturn and restricted bank lending in Europe, experts fear that the mountain of unpaid bills will drive up insolvency and job losses, reduce cross-border trade and snuff out any recovery.
-
DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.
-
*Elan, Theravance reach royalties deal. NEW YORK, May 13- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from its most recent record high, ahead of data on retail sales. *Investors will look to April retail sales data at 8:30 a.m. for any signs of strength in the consumer.
-
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline.
-
*Elan to acquire newly approved Breo as part of $1 bln deal. DUBLIN, May 13- Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline for its respiratory drugs.
-
May 10- The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both. The drug, Breo, is an inhaled treatment made by British drugmaker GlaxoSmithKline Plc and Theravance Inc of the United States.
-
PARIS, May 9- European shares fell in early trade on Thursday, halting a sharp three-week rally to multi-year highs, with pharmaceutical stocks trimming recent lofty gains. GlaxoSmithKline and AstraZeneca were both down 0.5 percent.
-
May 7- Three months ended March 31. Net Profit 1.69 vs 1.23 Net Sales 6.32 vs 6.23 EPS 20.0 vs 14.5 Results are standalone NOTE: GlaxoSmithKline Pharmaceuticals Ltd is a drugmaker. *Source text:* Further company coverage ().
-
*Blue-chip shares such as Reliance Industries Ltd. *Reliance Industries is up 1 percent while ITC Ltd. *Foreign institutional investors were net buyers of 8.97 billion rupees of stocks on Monday, taking the 2013 net buying to a total of $12.17 billion, provisional exchange data showed.